The clinical value of plasma soluble tumour necrosis factor related apoptosis inducing ligand level in patients with systemic lupus erythematosus
10.3760/cma.j.issn.1007-7480.2019.10.002
- VernacularTitle: 系统性红斑狼疮患者血浆游离肿瘤坏死因子相关凋亡诱导配体的变化和临床意义
- Author:
Shufang WU
1
;
Zhuoya ZHANG
;
Saisai HUANG
;
Jingjing QI
;
Genhong YAO
;
Lingyun SUN
Author Information
1. Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Jiangsu 210008, China
- Publication Type:Journal Article
- Keywords:
Lupus erythematosus, systemic;
Tumor necrosis factor-related apoptosis inducing ligand;
Apoptosis
- From:
Chinese Journal of Rheumatology
2019;23(10):652-655
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the plasma level change of soluble tumor necrosis factor related apoptosis inducing ligand (sTRAIL) in patients with systemic lupus erythematosus (SLE) and its clinical significance.
Methods:Quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) was used to detect the mRNA expressions of TRAIL and TRAIL receptors-1 (TRAIL-R1) and TRAIL-R2 in the peripheral blood mononuclear cells (PBMCs) derived from active SLE patients (n=26) and healthy controls. Enzyme linked immuno sorbent assay (ELISA) was used to detect the plasma level of sTRAIL in the active SLE patients (n=42), healthy controls (n=21). Pearson correlation analysis was used to analyze the correlation of sTRAIL with clinical and laboratory parameters.
Results:The plasma levels of sTRAIL [(82±5) pg/ml] in SLE were significantly higher than that in healthy controls [(49±3) pg/ml], the difference was statistically significant (t=4.10, P<0.01). The plasma levels of sTRAIL in SLE with inactive disease [(92±14) pg/ml], mild active disease [(80±9) pg/ml], moderate active disease [(74±12) pg/ml] and severe active disease [(83±8) pg/ml] were higher than healthy controls, the difference was statistically significant (H=18.07, P<0.01). The mRNA levels of TRAIL and TRAIL-R2 in PBMCs derived from SLE patients were significantly higher than those in healthy controls [(1.04±0.08) vs (1.80±0.25), t=2.10, P<0.05 and (1.07±0.12) vs (2.08±0.21), t=3.27, P<0.01]. In SLE with moderate and severe active disease, plasma sTRAIL levels were associated with the 24 hours urine protein.
Conclusion:Plasma sTRAIL may be predictors of SLE disease activity and TRAIL pathway may be a new potential target of SLE treatment.
